Novo Nordisk CFO: Company Already Meeting US Govt Demands on Drug Prices

Novo Nordisk's CFO, Karsten Munk Knudsen, states that the company is already meeting some of the demands set by Donald Trump to reduce drug prices in the US. The drugmaker is following the US government's guidelines, but the CFO did not elaborate on which specific demands Novo Nordisk is meeting.

In a recent development, Novo Nordisk's Chief Financial Officer (CFO), Karsten Munk Knudsen, has indicated that the company is already adhering to some of the demands set by President Donald Trump to reduce drug prices in the United States. While Knudsen did not specify which demands Novo Nordisk is meeting, the statement underscores the company's commitment to align with the U.S. government's guidelines on drug pricing.

Trump's demands, outlined in a series of letters to major pharmaceutical companies, include adopting "most-favored-nation" (MFN) pricing for existing and new drugs, repatriating revenues from other countries to lower U.S. drug prices, and applying MFN pricing for direct-to-consumer prescription drugs [1]. These demands aim to lower drug prices for American consumers and align U.S. prices with those in other developed countries.

Novo Nordisk, known for its blockbuster weight-loss drug Wegovy, has been facing pressure from compounding pharmacies and rival Eli Lilly, which have been producing copycat versions of Wegovy. The company has taken legal actions against these compounding pharmacies and has reiterated its full-year earnings expectations despite a recent profit warning [2].

The company's commitment to meet Trump's demands is significant, especially given the potential impact on its market position and stock performance. While Knudsen's statement does not provide specific details on which demands are being met, it indicates a proactive stance on the part of Novo Nordisk to address the government's concerns.

Investors and financial professionals should closely monitor the developments, as the company's compliance with these demands could influence its stock price and market valuation. The stock market's reaction to Trump's demands has been mixed, with some pharmaceutical companies experiencing stock price drops, reflecting investor concerns over potential price cuts and market share erosion [1].

For more information on Novo Nordisk's financial performance and the impact of Trump's drug pricing demands, please refer to the following sources:

[1] https://www.forbes.com/sites/antoniopequenoiv/2025/07/31/pharma-companies-should-immediately-cut-down-drug-prices-trump-says/
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-maker-novo-nordisk-warns-continued-copycat-drug-challenge-new-ceo-readied-2025-08-06/